Browsing by Author "Degirmenci, S"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    Doxorubicin functionalized metallic nanoparticles for anticancer and antibacterial applications
    Yesil, I; Atmaca, H; Degirmenci, S; Çamli-Pulat, C; Ari, M; Tepe, M; Küçük, A; Salmanoglu, DS; Sancak, Z; Kilinç, C; Ilhan, S; Yazgan, I
    In this study, we used Doxorubicin, an FDA approved drug possessing anticancer and antibacterial activity, as a model drug to functionalize sugar ligand synthesized silver/gold bimetallic nanoparticles (Ag/AuNPs) to test simultaneous antibacterial and anticancer activities under in vitro conditions. DU-145 prostate cancer cells were used as the main target while T98G glioblastoma and MDA-MB-231 breast cancer cell lines were used for selectivity test, and HEK-293 epithelial cell line was used as non-cancerous cells to test toxicity of these formulations. Three Ag/AuNP and corresponding Doxorubicin (D) functionalized ones and free Doxorubicin were tested for these four cell lines. Plain Ag/AuNP showed the highest toxicities on HEK-293 cell lines while DU-145 cell line showed the greatest vulnerability for Ag/AuNP-D formulations. However, DU-145 cells showed the lowest susceptibility for free Doxorubicin at all the tested concentrations. The antiproliferative activity was not dose dependent while an inverse relationship was obtained for a certain concentration range. Two Doxorubicin functionalized gold nanoparticles (AuNP-D) were then synthesized and applied on DU-145 cells. Interestingly, a better anticancer activity was obtained even at the minimum applied concentration (1.8 x 10-5 mu g/mL D). Antibacterial activities of these formulations were also tested for multidrug-resistant gram (-) and gram (+) bacterial species. Depending on the sugar ligand chemistry, antibacterial activity of Doxorubicin functionalized Ag/AuNPs showed a better performance in comparison to the plain Ag/AuNPs and vice-versa. Based on the results, it can be claimed that selective or semi-selective formulations targeting cancer cells and bacterial species as anti-neutropenia formulations can be developed using carbohydrate derivatives synthesized metallic nanoparticles as drug delivery agents.
  • No Thumbnail Available
    Item
    Sexual dysfunction in patients with allergic rhinoconjunctivitis
    Kirmaz, C; Aydemir, O; Bayrak, P; Yuksel, H; Ozenturk, O; Degirmenci, S
    Background: Sexual dysfunction in chronic diseases has recently attracted attention owing to its impact on quality of life (QoL). Allergic rhinoconjunctivitis (ARC) affects QoL, causing limitations in many areas. However, there has not been research on changes in sexual function in patients with ARC. Objective: To report the effect of ARC and its treatment on sexual function in men and women. Methods: Forty-three sexually active patients with seasonal ARC aged 22 to 49 years were included in the study. The control group was composed of 40 healthy individuals aged 22 to 46 years. Conjunctival symptom scores (CSSs) and nasal symptom scores (NSSs) of patients with symptomatic ARC were determined, as were sexual function scores (SFSs) using the Female Sexual Function Index and the International Index of Erectile Function during allergen exposure in the pollination period and after treatment with oral desloratadine, 5 mg/d, for 30 clays. The SFSs were evaluated in the control group. Results: The CSSs and NSSs significantly improved in treated ARC (P < .001). In women, Female Sexual Function Index results in symptomatic ARC were significantly lower than in treated ARC and controls (P = .003). In men, International Index of Erectile Function results in treated ARC (P = .001) and controls (P < .001) were significantly higher than in symptomatic ARC. Furthermore, correlation between improvement in CSSs and NSSs and that of SFSs was determined (P =.007 for women; P =.001 for men). Conclusion: Improvement in sexual function as a variable of QoL may accompany the treatment of symptoms in patients with ARC.